Market is forward looking. To me $25 is fair price now GIA. I think they can earn $2 a share in 2021 and be growing fast so 20 P/E reasonable so $40 then, if they ramp sales sooner....., if it takes longer it gets to $40 later. If they can settle generic and get label exactly what they want the $30 is possible sooner due to the upside being higher.
If there is a BO that won't happen for less then $40 and that can happen anytime though more so early next year. Probably the #1 middle-large acquisition target out there in Biotech. That definitely props the price up but it's because the drug has great potential.
All adds to about $25 a share to me today and $30 a share maybe in a year and then $40 the next year after.
The potential is Huge but the situation is unique so really hard to understand how sales will actually accelerate. GIA would be fun/intriguing to watch play out. Not sure some people could handle long term GIA emotionally HA. I think by time Amarin is clearly going it alone, if they do, the sales will keep the stock price up.
News 
Market Data 
Discover 
AI
